Disclaimer: This article is intended solely for informational and educational purposes only. It does not constitute medical advice.
Acetaminophen, also known as paracetamol or by the brand name Tylenol, is among the most widely used over-the-counter medications for the treatment of fever and mild pain. It is also used in the perioperative setting for analgesia. For decades, it was assumed that acetaminophen worked through the inhibition of cyclooxygenase (COX), as non-steroidal anti-inflammatory drugs (NSAIDs) do. This model has largely fallen out of favor because acetaminophen is a weak inhibitor of COX-1 and COX-2, does not meaningfully suppress neutrophil activation, and lacks clinically relevant anti-inflammatory or antiplatelet activity (Ohashi and Kohno, 2020; Anderson, 2008).
Furthermore, the proposed existence of an acetaminophen-sensitive COX-3 isoform, first described in canine cerebral cortex, has not held up in humans, where the corresponding gene product lacks COX activity altogether (Anderson, 2008). This article summarizes the current understanding of the molecular mechanism underlying acetaminophen for analgesia.
Current mechanistic understanding centers on acetaminophen’s biotransformation into an active metabolite. After hepatic deacetylation to p-aminophenol, the compound crosses the blood-brain barrier and is conjugated with arachidonic acid by fatty acid amide hydrolase to form N-arachidonoylphenolamine, commonly known as AM404 (Ohashi and Kohno, 2020; Anderson, 2008). AM404 acts as an indirect cannabinoid agonist by inhibiting anandamide reuptake and, more importantly, functions as an activator of the transient receptor potential vanilloid 1 (TRPV1) channel in the brainstem and midbrain, structures long implicated in descending pain modulation.
Beyond its supraspinal actions, more recent work using in vivo and in vitro whole-cell patch-clamp recordings has demonstrated that AM404 also acts directly within the spinal dorsal horn, where it suppresses excitatory synaptic transmission at C-fiber terminals synapsing onto substantia gelatinosa neurons via TRPV1 receptors, with these effects amplified in models of inflammatory pain (Ohashi and Kohno, 2020).
A second, independently supported mechanism implicates the descending serotonergic system. Acetaminophen increases serotonin turnover in the pons and cortex, and its antinociceptive effect in rodents is substantially attenuated by lesioning bulbospinal serotonergic pathways (Anderson, 2008).
This hypothesis received direct support when researchers demonstrated that co-administration of the 5-HT3 receptor antagonists tropisetron and granisetron completely abolished the analgesic effect of a 1-gram oral dose of acetaminophen in healthy volunteers, without altering acetaminophen’s pharmacokinetics, indicating a pharmacodynamic rather than pharmacokinetic interaction (Pickering et al., 2006). This finding provided the first direct human evidence that acetaminophen’s analgesic action depends on an intact spinal serotonergic relay, complementing the TRPV1/cannabinoid pathway rather than replacing it.
The converging molecular mechanisms of acetaminophen have implications for clinical analgesia. Because acetaminophen’s actions are predominantly central rather than peripheral, its analgesic ceiling and interaction profile differ from those of NSAIDs, and its opioid-sparing effect, while real, is modest. A meta-analysis of postoperative patient-controlled analgesia trials found that adding acetaminophen to morphine reduced 24-hour morphine consumption by approximately 20% (a mean reduction of 9 mg) but did not significantly reduce the incidence of opioid-related adverse effects such as nausea, vomiting, sedation, or urinary retention (Remy et al., 2005).
This modest but non-trivial benefit is consistent with a drug whose analgesic ceiling reflects saturable central mechanisms rather than peripheral anti-inflammatory action, and it underscores that acetaminophen should be regarded as a complementary, centrally acting component of multimodal analgesia rather than a substitute for opioids or NSAIDs in patients with significant inflammatory pain.
References
- Ohashi, N., & Kohno, T. (2020). Analgesic effect of acetaminophen: A review of known and novel mechanisms of action. Frontiers in Pharmacology, 11, 580289. https://doi.org/10.3389/fphar.2020.580289
- Anderson, B. J. (2008). Paracetamol (acetaminophen): mechanisms of action. Pediatric Anesthesia, 18(10), 915–921. https://doi.org/10.1111/j.1460-9592.2008.02764.x
- Pickering, G., Loriot, M. A., Libert, F., Eschalier, A., Beaune, P., & Dubray, C. (2006). Analgesic effect of acetaminophen in humans: First evidence of a central serotonergic mechanism. Clinical Pharmacology & Therapeutics, 79(4), 371–378. https://doi.org/10.1016/j.clpt.2005.12.307
- Remy, C., Marret, E., & Bonnet, F. (2005). Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. British Journal of Anaesthesia, 94(4), 505–513. https://doi.org/10.1093/bja/aei085